Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions

Area of Science:

• Pharmacovigilance and Regulatory Science
• Drug Safety and Risk Management

Background:

• The global regulatory landscape for product safety is intricate and subject to continuous change.
• Harmonization efforts have been made, but regional regulations and guidance continue to evolve.

Purpose of the Study:

• To provide a comprehensive overview of the global and regional regulatory framework for product safety.
• To identify long-term trends in regulatory review and their implications for drug safety.

Main Methods:

• Historical review of regulatory developments in product safety.
• Analysis of shifts from single-case adverse event review to aggregate data evaluation.
• Examination of global and regional regulatory perspectives.

Main Results:

• A significant trend is the move from reviewing individual serious adverse events to evaluating aggregate data.
• This shift facilitates interdisciplinary collaboration and bridges pre- and post-marketing surveillance.
• Opportunities arise for proactive identification of patient populations with favorable benefit-risk profiles.

Conclusions:

• The evolving regulatory framework necessitates interdisciplinary approaches to aggregate safety evaluation.
• Future work focuses on developing solutions for ongoing aggregate safety assessment.
• Enhanced collaboration can improve proactive benefit-risk management in product safety.